Recently, the JLABS Global CEO Summit was successfully held by Johnson & Johnson Innovation at the iconic New York Stock Exchange (NYSE) in New York City. Dr. Lily Zou, CEO & Co-founder of Degron Therapeutics, was invited to attend this prestigious event and honored with the JLABS Deal of the Year Innovation Award for the $1.2B collaboration between Degron Therapeutics and Takeda Pharmaceuticals to discover and develop novel molecular glue degraders for multiple disease targets.

The JLABS Global CEO Summit brought together CEOs from current and alumni JLABS companies, J&J leadership, investors and key stakeholders from around the globe. United in purpose and driven by innovation, they engaged in fruitful exchanges of expertise, fostered collaborations, celebrated collective achievements, and charted the course for the future of healthcare industry.

The JLABS Innovation Awards ceremony was a powerful moment to honor the exceptional achievements. This award celebrates those whose pursuit of advancing their science serves as an inspiration to others, demonstrating the power of persistence and tenacity to drive remarkable breakthroughs. Degron Therapeutics and its CEO, Dr. Lily Zou, stood out among over 100 global companies, earning this prestigious award due to their continuous innovation and breakthroughs.

About Degron Therapeutics
Degron Therapeutics uses its molecular glue-based targeted protein degradation drug discovery platform to develop novel medicines and advance human health. The company’s unique GlueXplorer® platform encompasses a rapidly expanding IP-protected compound library and screening systems to develop a new class of small-molecule medicines that target important disease targets, including those previously undruggable. The company’s pipeline comprises a growing number of preclinical programs for oncology, inflammation, metabolic disorders, and rare diseases. For more information, please visit www.degrontx.com.